Losartan + Sunitinib in Treatment of Osteosarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

August 31, 2026

Study Completion Date

February 28, 2027

Conditions
Osteosarcoma
Interventions
DRUG

Losartan

Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily, dose level 2 dosing will not exceed 100 mg daily, and dose level 3 dosing will not exceed 150 mg total daily (75 mg twice daily). Doses should be taken at approximately the same time daily and patients should fast for at least 4 hours prior to dosing

DRUG

Sunitinib

Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2. Sunitinib is given as capsules or liquid formulation. Doses should be taken at approximately the same time daily.

Trial Locations (4)

30322

RECRUITING

Children's Hospital of Atlanta, Atlanta

80045

RECRUITING

Children's Hospital Colorado, Aurora

RECRUITING

University of Colorado Hospital, Aurora

90027

NOT_YET_RECRUITING

Children's Hospital Los Angeles, Los Angeles

All Listed Sponsors
collaborator

Cancer League of Colorado

OTHER

collaborator

Colorado State University

OTHER

collaborator

Swim Across America

OTHER

lead

University of Colorado, Denver

OTHER